Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens

International Immunology

Volumn 26, Issue 10, 2014, Pages 531-538

  Sheppard, Neil C ^a,d   Brinckmann, Sarah A ^a   Gartlan, Kate H ^a   Puthia, Manoj ^b   Svanborg, Catharina ^b   Krashias, George ^a   Eisenbarth, Stephanie C ^c   Flavell, Richard A ^c   Sattentau, Quentin J ^a   Wegmann, Frank ^a,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GLAXOSMITHKLINE   (United States)

^e CRUCELL HOLLAND BV   (Netherlands)

Author keywords

adaptive immunity; innate immunity; PEI; vaccine; virus

Indexed keywords

ANTIBODY; ANTIGEN; CPG-OLIGONUCLEOTIDE; CYTOKINE; GLYCOPROTEIN; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; POLYETHYLENEIMINE; VIRUS ENVELOPE PROTEIN;

ANIMAL; ANTIGEN PRESENTING CELL; BIOSYNTHESIS; IMMUNIZATION; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; NEUTROPHIL CHEMOTAXIS; RABBIT; T LYMPHOCYTE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGEN-PRESENTING CELLS; ANTIGENS; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GLYCOPROTEINS; IMMUNIZATION; MICE; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; POLYETHYLENEIMINE; RABBITS; T-LYMPHOCYTES; TH1 CELLS;

EID: 84918835260     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxu055     Document Type: Article

References (30)

1. Guy, B. 2007. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5:505.
2. Pashine, A., Valiante, N. M. and Ulmer, J. B. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(Suppl. 4):S63.
3. Wegmann, F., Gartlan, K. H., Harandi, A. M. et al. 2012. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat. Biotechnol. 30:883.
4. Montefiori, D. C. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 12:11.
5. Kircheis, R., Wightman, L. and Wagner, E. 2001. Design and gene delivery activity of modified polyethylenimines. Adv. Drug Deliv. Rev. 53:341.
6. Lungwitz, U., Breunig, M., Blunk, T. and Göpferich, A. 2005. Polyethylenimine-based non-viral gene delivery systems. Eur. J. Pharm. Biopharm. 60:247.
7. Hubbell, J. A., Thomas, S. N. and Swartz, M. A. 2009. Materials engineering for immunomodulation. Nature 462:449.
8. Sok, D., Laserson, U., Laserson, J. et al. 2013. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog. 9:e1003754.
9. Mascola, J. R. and Montefiori, D. C. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413.
10. Kong, L. and Sattentau, Q. J. 2012. Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. J. AIDS Clin. Res. S8:3.
11. Kwong, P. D., Mascola, J. R. and Nabel, G. J. 2011. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 1:a007278.
12. Kool, M., Soullié, T., van Nimwegen, M. et al. 2008. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205:869.
13. ur Rehman, Z., Sjollema, K. A., Kuipers, J., Hoekstra, D. and Zuhorn, I. S. 2012. Nonviral gene delivery vectors use syndecandependent transport mechanisms in filopodia to reach the cell surface. ACS Nano. 6:7521.
14. Hanagata, N. 2012. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int. J. Nanomedicine 7:2181.
15. Boussif, O., Lezoualc’h, F., Zanta, M. A. et al. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92:7297.
16. McElrath, M. J. and Haynes, B. F. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542.
17. Sonawane, N. D., Szoka, F. C. Jr and Verkman, A. S. 2003. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 278:44826.
18. Kircheis, R., Blessing, T., Brunner, S., Wightman, L. and Wagner, E. 2001. Tumor targeting with surface-shielded ligand–polycation DNA complexes. J. Control. Release 72:165.
19. Cassel, S. L., Eisenbarth, S. C., Iyer, S. S. et al. 2008. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl Acad. Sci. USA 105:9035.
20. Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T. and Tschopp, J. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674.
21. Hornung, V., Bauernfeind, F., Halle, A. et al. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9:847.
22. Lambrecht, B. N., Kool, M., Willart, M. A. and Hammad, H. 2009. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21:2.
23. McKee, A. S., Munks, M. W., MacLeod, M. K. et al. 2009. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 183:4403.
24. Franchi, L. and Núñez, G. 2008. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38:2085.
25. Chen, J., Li, Z., Huang, H. et al. 2011. Improved antigen cross-presentation by polyethyleneimine-based nanoparticles. Int. J. Nanomedicine 6:77.
26. Chorny, A., Puga, I. and Cerutti, A. 2010. Innate signaling networks in mucosal IgA class switching. Adv. Immunol. 107:31.
27. Haynes, B. F., Gilbert, P. B., McElrath, M. J. et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275.
28. Tomaras, G. D., Ferrari, G., Shen, X. et al. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl Acad. Sci. USA 110:9019.
29. Lipford, G. B., Sparwasser, T., Bauer, M. et al. 1997. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27:3420.
30. + T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J. Control. Release 150:307.